12 news items
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
BMY
EVO
LLY
20 Jun 24
. (NYSE:LLY), focusing on developing treatments for chronic kidney disease, neuroscience, and metabolic disorders.
Most
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
BMY
4 Jun 24
include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity
Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
BMY
3 Jun 24
at least one prior line of therapy, and for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after two
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY
3 Jun 24
complications include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity
FDA Expands Approval For Bristol Myers Squibb's Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies
BMY
31 May 24
for Breyanzi for relapsed or refractory chronic lymphocytic leukemia
x0iiwvlv05bi7to6
BMY
30 May 24
, and has received accelerated approval for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after
hjpngqze7yh3e0v3fopwnciwi750txkgk5 c3jm8
BMY
23 May 24
(lisocabtagene maraleucel), demonstrating consistent clinical outcomes in relapsed/refractory chronic lymphocytic
ht9kl4nj0h6u0x6g1eu1sr6pnze5 fn9wmot68ivqut2ujn
BMY
16 May 24
that provides sustained relief from this chronic disease, allowing patients to prioritize other aspects of their daily lives. These findings further reinforce
7nwnn6uq2cg88wzpyupvo3wlg4vglt2eko1zoc7fq9mb6eq3adqaiq57wn
BMY
15 May 24
lymphoma (LBCL) after at least one prior line of therapy and received accelerated approval for the treatment of relapsed or refractory chronic lymphocytic
263ahpbu
BMY
10 May 24
hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning
3scbwrb i6njnbmwu
BMY
26 Apr 24
(GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome
g83951kahpteqrlipshgga6pf3lu9u
BMY
25 Apr 24
of Abecma in Earlier-Line Multiple Myeloma and Breyanzi in Chronic
- Prev
- 1
- Next